Wei Daiqing, Li Cui, Ye Junwu, Xiang Feifan, Liu Juncai
Department of Orthopaedics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Sichuan Provincial Laboratory of Orthopaedic Engineering, Luzhou, Sichuan, People's Republic of China.
Cancer Manag Res. 2020 Nov 24;12:12067-12075. doi: 10.2147/CMAR.S273466. eCollection 2020.
Osteosarcoma development is a complex set which is determined by various factors. Many patients suffered from sustained osteosarcoma growth and revealed poor response to clinical interventions. However, the underlying mechanisms of osteosarcoma development still remain unclear.
In our study, we isolated osteosarcoma tissues from clinical patients, which were divided into high degree group (stage G1~G2) and low degree group (stage G0). The expression of type I collagen, integrin and STAT3 in tumor tissues were analyzed by immunohistochemistry or immunofluorescence. The collagen-induced cells proliferation was detected by CCK8 and colony formation analysis. The activation of JAK/STAT3 signal was examined by Western blotting and immunofluorescence. The anticancer effects of integrin α2β1 peptide were analyzed by Sao-2-bearing mice model.
Our results implicated that type I collagen could facilitate malignant osteosarcoma development in patients. In vitro, 2D collagen culture also efficiently mediated the stemness up-regulation of osteosarcoma cells, resulting in the strengthened capability of cells proliferation and tumorigenesis. In mechanism, we found that type I collagen could facilitate the activation of JAK/STAT3 signals through integrin α2β1, which elicited tumor-sustained growth and cancer relapse. In tumor-bearing mice model, integrin α2β1 signals inhibitor significantly suppressed the osteosarcoma cells proliferation and their tumorigenic ability, which improved the outcome of chemotherapy/radiotherapy.
Our study demonstrated that type I collagen could mediate osteosarcoma development through an integrin α2β1/JAK/STAT3 signaling pathway. Blockade of integrin α2β1 by α2β1 inhibitor efficiently improved outcome of chemotherapy/radiotherapy, which provided new insights for eradicating tumors in clinic.
骨肉瘤的发生是一个由多种因素决定的复杂过程。许多患者的骨肉瘤持续生长,对临床干预反应不佳。然而,骨肉瘤发生的潜在机制仍不清楚。
在我们的研究中,我们从临床患者中分离出骨肉瘤组织,将其分为高度组(G1~G2期)和低度组(G0期)。通过免疫组织化学或免疫荧光分析肿瘤组织中I型胶原蛋白、整合素和STAT3的表达。通过CCK8和集落形成分析检测胶原蛋白诱导的细胞增殖。通过蛋白质免疫印迹法和免疫荧光检测JAK/STAT3信号的激活。通过荷Sao-2小鼠模型分析整合素α2β1肽的抗癌作用。
我们的结果表明,I型胶原蛋白可促进患者恶性骨肉瘤的发展。在体外,二维胶原蛋白培养也有效地介导了骨肉瘤细胞干性的上调,导致细胞增殖和肿瘤发生能力增强。在机制上,我们发现I型胶原蛋白可通过整合素α2β1促进JAK/STAT3信号的激活,从而引发肿瘤的持续生长和癌症复发。在荷瘤小鼠模型中,整合素α2β1信号抑制剂显著抑制了骨肉瘤细胞的增殖及其致瘤能力,改善了化疗/放疗的效果。
我们的研究表明,I型胶原蛋白可通过整合素α2β1/JAK/STAT3信号通路介导骨肉瘤的发展。α2β1抑制剂阻断整合素α2β1可有效改善化疗/放疗效果,为临床根除肿瘤提供了新的思路。